Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06697223 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.
A Phase 2 study of Healthy Subjects, sponsored by Cerus Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT06697223: Completed Phase 2 study of Healthy Subjects, sponsored by Cerus Corporation.
NCT06697223 is a Phase 2 study of Healthy Subjects that has completed, run by Cerus Corporation. The registered enrollment target is 40 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (69% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06697223, a Phase 2 study of Healthy Subjects, has completed, sponsored by Cerus Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of this study is to assess the post-infusion recovery and survival of platelets in 100% Plasma treated with INTERCEPT Blood System for Platelets with LED Illuminator and stored for 5 days after apheresis collection. The post-infusion recovery and survival of autologous radiolabeled 5-day INTERCEPT platelets (Test) stored in 100% plasma will be measured in comparison to fresh autologous radiolabeled platelets (Control).
Primary Outcome
Recovery of Test platelets stored for 5 Days as compared to fresh controls. In vivo recovery was expressed as proportion of infused in days and was estimated using a multiple-hit model. The FDA acceptance criteria for survival is \>66% of control with the lower bound of a two-sided 95% CI for the mean treatment difference (Test-0.66\*Control) in survival is greater than or equal to zero.
Conditions Studied
Interventions
- DEVICE INTERCEPT Blood System for Platelets with LED Illuminator
Study Locations (2)
Virginia
- American Red Cross Research Laboratory - Norfolk
Washington
- Bloodworks Northwest Research Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2025-06-13 |
| Phase | Phase 2 |
What the finished NCT06697223 record still lists
NCT06697223 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 1 intervention - of which INTERCEPT Blood System for Platelets with LED Illuminator is the first listed.
NCT06697223 reports a single indexed study location in Virginia, Washington.
Frequently Asked Questions
What is clinical trial NCT06697223 about?
NCT06697223 is a clinical study titled "A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.". The objective of this study is to assess the post-infusion recovery and survival of platelets in 100% Plasma treated with INTERCEPT Blood System for Platelets with LED Illuminator and stored for 5 days after apheresis collection. The post-infusion recovery and survival of autologous radiolabeled 5-d...
What is the current status of trial NCT06697223?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-01-23. Estimated completion is 2025-06-13.
What conditions does trial NCT06697223 study?
This clinical trial studies the following conditions: Healthy Subjects.
What interventions are being tested in trial NCT06697223?
The interventions under investigation include: INTERCEPT Blood System for Platelets with LED Illuminator (DEVICE).
Who is sponsoring clinical trial NCT06697223?
This trial is sponsored by Cerus Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06697223 being conducted?
This trial has 2 study locations across Virginia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06697223's enrollment target sits among peer trials
40 30th of 69 higher than 39 of 69 other Healthy Subjects trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Subjects trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1
RECRUITING · Phase 2
-
Effect of a Commercial Cosmetic Mouth Rinse on Plaque Re-growth
COMPLETED · Phase 2
-
Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
RECRUITING
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
Radiocaine Safety Study In Healthy Human Subjects
RECRUITING · Early Phase 1
-
Optimizing Ultrasound-induced Anti-inflammation in Human Subjects
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI